Japan records surprise trade deficit in July as exports weaken further
Investing.com -- Shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX, TSX:BCT) surged 80% after the company announced a confirmed 100% resolution of lung metastasis in a breast cancer patient treated with Bria-OTS, its novel immunotherapy. The patient, part of a Phase 1/2a study, showed complete resolution of the lung tumor after two months of treatment, with the outcome sustained at the four-month follow-up.
The clinical-stage biotech firm reported that the 78-year-old patient with hormone receptor-positive, HER2-negative metastatic breast cancer responded well to the Bria-OTS monotherapy. The patient had previously failed several lines of therapy and received the lowest dose level in the study. Despite extensive metastases at enrollment, including bone, lymph node, and lung involvement, the patient achieved complete resolution of lung metastasis with stable disease elsewhere after receiving intradermal injections of Bria-OTS.
Dr. Neal S. Chawla, Director at the Sarcoma Oncology Center and Principal Investigator for the Bria-OTS study, expressed excitement over the initial data, which showed rapid and strong anti-tumor activity. The results provide early validation of BriaCell’s personalized immunotherapy approach, according to Dr. William V. Williams, President and CEO of BriaCell.
Bria-OTS is currently being investigated as a personalized off-the-shelf immunotherapy in a Phase 1/2a dose escalation study for metastatic recurrent breast cancer. The study will evaluate the safety and efficacy of Bria-OTS as monotherapy before proceeding to test it in combination with an immune checkpoint inhibitor.
The company’s lead candidate, Bria-IMT™, is also in a pivotal Phase 3 study for metastatic breast cancer. The positive outcome from the Bria-OTS study appears to support the potential of BriaCell’s immunotherapy platform and has clearly resonated with investors, as reflected in the significant stock price increase.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.